References in periodicals archive ?
Arformoterol mitigates the Cl[sub]2 toxicity on airway reactivity and alveolar fluid clearance by increasing lung cyclic AMP level.[17] Rolipram inhibits degradation of the intracellular signaling molecule cyclic AMP, which alleviates pulmonary edema, inflammation, and AHR.[37]
Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): Occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
Sunovion's track record of discovery, development and commercialization of important therapies has included Brovana (arformoterol tartrate), Latuda (lurasidone HCI), and most recently Aptiom (eslicarbazepine acetate).
It must be remembered that the later adrenergic agents (albuterol, bitolterol, pirbuterol, levalbuterol, salmeterol, formoterol, and arformoterol) are much more beta 2 specific than previous agents such as epinephrine and isoetherine.
arformoterol (for nebuliser use), and carmoterol, indacaterol, and new long-acting anticholinergics (10)
(24) Although not commercially available at the time when my patients were transitioned to BIS, arformoterol tartrate inhalation solution 15 [micro]g/2 mL (Brovana[R]; Sepracor Inc, Marlborough, MA) also has been shown to be stable physically and chemically when mixed with BIS 0.25 mg/2 mL or 0.5 mg/2 mL.
A New Drug Application (NDA) for arformoterol tartrate inhalation solution remains under review at the FDA.
* long-acting [[beta].sub.2]-agonists (LABAs), such as arformoterol, indacaterol, formoterol, olodaterol, salmeterol, and vilanterol
Long-acting agents, such as salmeterol, formoterol, and arformoterol are indicated for maintenance bronchodilation and control of bronchospasm, and for control of nocturnal symptoms in asthma or other obstructive diseases.
Arformoterol - Sepracor has completed more than 100 preclinical studies and 16 clinical studies for arformoterol inhalation solution as a maintenance treatment for COPD.
(5,12,13) In a study of patients receiving formoterol 12 meg compared with 15-mcg and 25-mcg doses of arformoterol, those taking formoterol had a lower exacerbation rate than those on either strength of arformoterol (22% vs 32% and 31%, respectively).
Arformoterol is the latest b2-selective agonist with a long-acting bronchodilatory effect of up to 12 hours in duration.